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Targeted imaging of integrins in cancer tissues
using photocleavable Ru(II) polypyridine
complexes as mass-tags†
Jiaying Han,a Jing Sun,b Shanshan Song,a Leonie Beljaars,a Geny M. M. Groothuis,a
Hjalmar Permentier,a Rainer Bischoff, a Gyorgy B. Halmos, c
Cornelia J. Verhoeven, c Erika R. Amstalden van Hove,de Peter Horvatovich *a
and Angela Casini *af
Targeted epitope-based mass spectrometry imaging (MSI) utilizes
laser cleavable mass-tags bound to targeting moieties for detecting
proteins in tissue sections. Our work constitutes the first proof-of-
concept of a novel laser desorption ionization (LDI)-MSI strategy
using photocleavable Ru(II) polypyridine complexes as mass-tags
for imaging of integrins avb3 in human cancer tissues.
Imaging the distribution of specific proteins in tissues can
provide new insights into biological processes related to the
functioning of cells, the molecular mechanisms of diseases and
drug action, and can also be used for diagnosis. Amongst the
possible investigational methods, mass spectrometry imaging
(MSI) constitutes a powerful and versatile technique for the
multiplexed analysis of a broad variety of molecules ranging
from metabolites (metabolomics), proteins (proteomics), metal
ions (metallomics) and pharmaceutical compounds.1–4 A powerful
technique in mass spectrometry for tissue section analysis is
matrix-assisted laser desorption ionization-mass spectrometry
imaging (MALDI-MSI),5–8 providing information about both the
simultaneous spatial distribution and relative abundance of
hundreds of unknown compounds within tissue sections.9 To
date, significant innovations, especially in instrumentation10 and
sample preparation protocols, have allowed analysis of both fresh,
frozen and formalin-fixed paraffin-embedded (FFPE) tissues
by MALDI-MSI.11 However, the application of this powerful
method is still restricted by several limitations stemming from
the nature of tissue samples, as well as from the MALDI-MSI
process.12 One of the main issues is the requirement of a matrix
and its preparation and deposition procedure, limiting the
ionization efficiency, reproducibility, spatial resolution, and
the detection of low abundant proteins, as well as the size of
the molecules detectable by the MALDI process.13
To achieve specific or targeted protein detection in tissue by
MSI, especially in FFPE tissues, an affinity-based strategy involving
the use of ‘mass-tags’ has been developed, wherein a probe is
directed against a specific molecular target. The probe features a
reporter group, namely a mass-tag, which is an encoding molecule
with a specific mass, released as a cation from the tissue during
the MALDI process. Usually, mass-tags are small molecules
(o1000 Da) with high ionization efficiency. Upon laser irradiation,
the mass-tag is cleaved from the targeting molecule on the
tissue surface, ionized and detected by mass spectrometry,
thus, providing indirect target identification with localization
information.14,15 Depending on the photocleavage efficiency,
the method can be performed also under matrix-free laser
desorption ionization (LDI) conditions.
Olejnik and coworkers developed the first photocleavable
(PC) mass-tags for targeted detection of proteins in 1998,16
whereby a specific antibody was tethered to a mass-tag through
a PC-linker, namely a 2-nitrobenzyl derivative. In 2007, Fournier
and coworkers15 reported mass-tag approaches for targeted
MALDI-MSI of proteins and mRNA in tissues with 4-[4-[1-(Fmoc-
amino)ethyl]-2-methoxy-5-nitrophenoxy]butanoic acid as PC-linker.
The mass-tag strategy was extended to different types of affinity
binders including antibodies, lectins or aptamers.17 Gut and
coworkers14 developed matrix-free TAMSIM (TArgeted multiplex
Mass Spectrometry IMaging) using trityl (triaryl methane) species
as mass-tags, forming resonance stabilized carbocations upon laser
irradiation. In 2012, Caprioli and coworkers18 developed an activity-
based MSI approach using reporter trityl mass tags, providing high
spatial resolution and sensitivity through the combination of signal
amplification chemistry and target specificity.
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Overall, photocleavable mass-tag strategies have been success-
fully implemented in the field of targeted imaging of proteins,
which can be applied independently from the protein mass and
ionization affinity.19,20 Moreover, this approach can be combined
with hybridization and affinity recognition techniques including
in situ hybridization of mRNA (ISH) and immunohistochemistry
(IHC). Despite these promising results, drawbacks of the mass-
tags developed to date include: (i) the preparation of the tags often
requires sophisticated and elaborate synthesis and purification
steps of the linker-reporter moiety, (ii) stability issues of the tag
itself (as in the case of TAMSIM14), (iii) lack of specific mass
spectral features such as the isotopic pattern to facilitate data
processing and compound identification.
In order to overcome the above-mentioned limitations, our
group developed a mass-tag constituted of a photocleavable
Ru(II) polypyridine complex tethered to a targeting peptide.
Upon photoexcitation, ruthenium polypyridyl compounds are
known to selectively photosubstitute one ligand of the coordi-
nation sphere by a solvent molecule.21–23 Therefore, upon UV
light activation inside the mass spectrometer ionization chamber,
a ruthenium-containing charged fragment is released from the
tagged peptidic moiety, providing a fingerprint signal in the MS
spectrum. Not only is the ionization efficiency of the photocleaved
positively charged Ru(II) fragment high, but the metal ion also has
a specific isotopic pattern distribution which renders its identifi-
cation unambiguous. Moreover, it was hypothesized that this
approach would enable matrix-free MSI. The absence of a matrix
simplifies the preparation of the tissue and facilitates improve-
ment of the MSI reproducibility, avoiding the interferences due to
the matrix crystallization process.
Following this approach, a PC Ru(II) polypyridyl complex was
bioconjugated to the cyclic cyc(RGDfK) peptide which specifi-
cally binds to integrins avb3.24,25 The expression of the latter
has been shown to correlate well with metastasis and tumor
neovascularization.26–29 In our study, the Ru(II) mass-tag was
used to image avb3 integrins in samples of hypopharynx tumor
tissue from a human patient with head and neck cancer. In this
type of cancer, avb3 integrins are not necessarily overexpressed
with respect to normal cells, but they have a characteristic
tumor tissue distribution as shown by previous IHC studies.30
Initially, an already reported synthetic route was used to prepare
the [RuII(terpy)(bpy)Cl]+ complex (1,31,32 Scheme 1) (see Experimental
section for details and Fig. S1, ESI†). Afterwards, the compound
was derivatized with biotin via exchange of the chlorido ligand
with a thioether group, with high affinity for Ru(II), following
a previously reported procedure.33 The Ru–biotin complex
[RuII(terpy)(bpy)(D-biotin)]2+ (2, Scheme 1 and Fig. S2, ESI†)
could then be further tethered to the targeting peptide by
amide bond formation, through the carboxylic moiety present
on the biotin ligand.
The synthesis of the bioconjugated targeted mass-tag
[RuII(terpy)(bpy)(D-biotin)(cyc(RGDfK))]2+ (3) was achieved by
directly conjugating 2 to the cyc(RGDfK) peptide by first activating
the Ru(II) compound via EDC (1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide) and sulfo-NHS (N-hydroxysulfosuccin-
imide) treatment, followed by addition of 1.1 equiv. of peptide
for 1.5 h at room temperature in the dark. Compound 3 was
purified on a C18 column and analyzed by HPLC-MS (see
Experimental for details and Fig. S3, ESI†). The UV-visible
absorption spectrum of compound 3 showed two typical bands
at 315 nm and 450 nm (Fig. S4, ESI†).
To investigate the feasibility of matrix-free LDI-MSI, the
photocleavable character of compound 3 (2 mg mL1) was assessed
by LDI-MS without matrix, with the compound deposed on an ITO
coated glass slide. Ruthenium species due to photocleavage of the
Ru mass-tag 3 upon UV laser irradiation are clearly detected
(Fig. S5, ESI†). A main monocharged species appears at m/z
567.087, which was attributed to a [RuII(terpy)(bipy)(pyridine)-3H]+
fragment. The latter is not unexpected since previous mass spectro-
metry studies, including LDI and MALDI MS, on similar Ru(II) poly-
pyridine complexes have shown that a bipyridine ligand may also
fragment, releasing a pyridine ring which can further react with the
ruthenium centre.34–36 As a result of this fragmentation, other
Ru(II)-pyridine species are detected in the mass spectrum (Fig. S5,
ESI†). Moreover, fragmentation of the terpy ligand has been
excluded based on the in depth analysis of the MS data and on
previously reported MS studies on similar complexes.37
The affinity of the Ru(II) mass-tag 3 for its target avb3
integrins (IC50 = 3.2  0.5 nM) was validated by an ELISA-type
solid-phase binding assay.25,38,39 The results also showed that 3
has much lower binding affinity for integrins a5b1 and avb5
(IC50 ca. 500 nM), indicating its selectivity.
The expression and distribution of integrin avb3 in tumor
samples was confirmed in tissue sections collected from
patients with hypopharyngeal squamous cell carcinoma using
IHC and hematoxylin staining. The results showed integrins
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avb3 were highly expressed (crimson color) in the tumor stroma
(Fig. S6, ESI†) in line with previous results.30 LDI-MSI experi-
ments were performed on three tissue sections incubated with
PBS buffer (pH 7.4), compound 2 or compound 3, respectively
(Fig. 1). The results were compared with IHC and hematoxylin
staining performed on adjacent tissue sections. The signifi-
cantly higher intensities of LDI signals in the sections treated
with compound 3 compared to the two other tissue sections
was confirmed in the intensity distribution diagrams of MS
peaks in the whole MSI dataset (ESI,† Fig. S7).
Incubating the tissue section with compound 3 resulted in a
clearly distinguishable signal corresponding to the distribution
of the mass-tag (Fig. 1C). It should be noted that the high
intensity signal of the Ru(II) polypyridine mass-tag (Fig. 1E),
features the same isotope pattern as the one from compound 3
(2 mg mL1) deposed on the ITO coated glass slide (Fig. S1,
ESI†). In the tissue, the distribution of the signal arising from
complex 3 correlates well with the distribution of avb3 integrins
based on IHC and hematoxylin staining (Fig. 1D and Fig. S8,
ESI†), while the LDI-MSI images of the control with PBS
(Fig. 1A) show no signal in the m/z range of the mass-tag.
Concerning tissue treated with compound 2 (Fig. 1B), unspecific
and scarcely intense Ru signals were detected due to residual
presence of the compound following the washing steps. These
results demonstrate that only the integrin targeted construct 3
results in the expected distribution of the mass-tag in the tissue
section, while compound 2, with only D-biotin as ligand, does
not bind to any specific region of the section.
In this proof-of-concept study, we propose a matrix-free
LDI-MSI strategy using a novel metal-based photocleavable
mass-tag targeted at integrin receptors, namely the ruthenium
complex 3 [RuII[(terpy)(bpy)(D-biotin)(cyc(RGDfK))]]2+. The
mass-tag of the Ru(II) polypyridine moiety provides a specific
isotopic pattern, enabling differentiation of the tag from back-
ground signals. Ideally this strategy may be extended to reveal
the spatial distribution of other proteins in tissue samples
without limitation of the mass range of the target analytes by
conjugating Ru(II) polypyridyl fragments [RuII[(terpy)(bpy)X]]
(X = PC linker) with different masses to various targeting
moieties. In fact, it is possible to diversify the Ru mass-tags
varying the terpy and bipy scaffolds (e.g. adding a substituent
on their aromatic rings) in order to have photocleaved
Fig. 1 LDI-MSI images of mass-tag from hypopharynx tumor tissue sections incubated with (A) PBS buffer (pH 7.4), (B) compound 2 [RuII(terpy)(bpy)-
(D-biotin)]2+ and (C) compound 3 [RuII(terpy)(bpy)(D-biotin)(cyc(RGDfK))]2+. Images were obtained with a m/z range of 560.43–571.91 Da, which covers all
isotopes of the Ru mass tags in the LDI spectrum. (D) avb3 IHC and haematoxylin stained section of a hypopharyngeal squamous cell carcinoma section.
The dark red staining represents the localization of the target integrin. (E) LDI mass spectrum of the mass-tag signal related to the image of sections
incubated with compound 3 (pixel coordinates: x 25, y 34, pixel ID 131). The inset shows the experimental isotopic pattern distribution of the main fragment
ion [Ru(terpy)(bipy)(pyridine)-3H]+ vs. the theoretical one (mass range from m/z 560 to 575). Images A, B and C were obtained with the ‘‘weak denoising’’
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fragments of different mass for every applied targeted mass-tag.
Each of the latter can be linked to a different targeting epitope
corresponding to different proteins of interest.
Further work is necessary to characterize the properties
of compound 3 [RuII[(terpy)(bpy)](D-biotin)(cyc(RGDfK))]2+ as
photocleavable mass-tag in LDI-MSI, such as its specificity in
different tissue samples and photocleavage yield. For its
potential application in multiplexed analysis of proteins in a
single measurement, Ru-based mass-tags have to be designed
with differently modified polypyridine ligands, featuring different
masses and bioconjugable to various targeting moieties.
Typically, the wavelengths of UV lasers used in MALDI-MS
instruments are 337 nm (nitrogen lasers), 355 nm or 266 nm
(frequency-tripled and quadrupled Nd:YAG lasers, respectively).
However, the judicious modification of the Ru(II) mass-
tag scaffold allows to induce photocleavage at different
wavelengths.40–42 For example, infra-red (IR) wavelengths may
be used, which may also allow deeper penetration of the
photons in living tissues. Moreover, the MSI spatial resolution
can be further improved, for example by using displacement
of the laser in smaller steps than the N2 laser beam diameter
(5–50 mm), using a laser beam of smaller diameter43 or applying
transmission geometry.44 In summary, we present here a new
photochemical tool for sensitive matrix-free targeted LDI-MSI
of proteins that may have far-reaching applications.
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Biol., 2008, 130, 421–434.
10 M. Niehaus, J. Soltwisch, M. E. Belov and K. Dreisewerd, Nat.
Methods, 2019, 16, 925–931.
11 F. Deutskens, J. Yang and R. M. Caprioli, J. Mass Spectrom., 2011, 46,
568–571.
12 P.-M. Vaysse, R. M. A. Heeren, T. Porta and B. Balluff, Analyst, 2017,
142, 2690–2712.
13 R. J. a. Goodwin, J. Proteomics, 2012, 75, 4893–4911.
14 G. Thiery, M. S. Shchepinov, E. M. Southern, A. Audebourg,
V. Audard, B. Terris and I. G. Gut, Rapid Commun. Mass Spectrom.,
2007, 21, 823–829.
15 R. Lemaire, J. Stauber, M. Wisztorski, C. Van Camp, A. Desmons,
M. Deschamps, G. Proess, I. Rudlof, A. S. Woods, R. Day, M. Salzet
and I. Fournier, J. Proteome Res., 2007, 6, 2057–2067.
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